Safety and efficacy of Edaravone[Nichiiko] in patients with acute noncardiogenic brain embolism - Safety and efficacy of Edaravone[Nichiiko] in patients with acute noncardiogenic brain embolism

Takeshi Yamada0 个研究点目标入组 20 人开始时间: 2010年12月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•the investigators must ensure that all subjects being considered to meet the following exclusion criteria or conditions: 1)difficult lifesaving in a coma 2)serum creatinine >= 1.5 mg/dL 3)history of allergy to Edaravone 4)cardiogenic brain embolism 5)hemorrhagic infarction, epidural hemorrhage, intracerebral hemorrhage, intraventricular hemorrhage 6)transient ischemic attack 7)patients are less than 3 months from the last onset in case of reappearance 8)mRS before the onset >= grade 2 9)patients who are administrated the excluded drugs between onset and investigational drug administration 10)patients who are recieved the excluded therapies between onset and investigational drug administration 11)A serious heart disease(e.g heart failure) or hepatic disease(e.g cirrhosis hepatis) to need hospitalization treatment 12)Patients have cancer 13)Patients who are or may be pregnant, who are lactating 14)recent (past 3 months) participation in other clinical trial for investigational agent,the investigator determines this trial participation inadequate

发起方

Takeshi Yamada